Decoding the medical terms and numbers in your pathology results
After a biopsy or surgery for a suspicious mole, the results come back as a pathology report—a dense, technical document full of terms like "Breslow depth," "mitotic rate," and "margins." For most patients, it reads like a foreign language at the exact moment they most need to understand it.
This guide walks through the key sections of a melanoma pathology report, what each finding means, and how they come together to shape your stage and treatment plan.
Most melanoma pathology reports include a "synoptic" section—a standardized checklist of findings. Here's what the most important entries mean:
This is the single most important number on the report: how deep the melanoma has grown, measured in millimeters from the top of the skin to its deepest point. Thinner melanomas (under 1 mm) carry an excellent prognosis, while thicker ones are treated more aggressively. Breslow depth is the main driver of your "T" (tumor) category in staging—see our guide on what your melanoma stage means for how this translates into Stage 0–IV.
Ulceration means the skin over the melanoma has broken down under the microscope—essentially, the tumor has outgrown its blood supply. Its presence is an independent sign of more aggressive behavior and can shift a tumor into a higher stage, even at the same thickness.
This counts how many tumor cells were caught in the act of dividing, per square millimeter. Older staging systems used mitotic rate to help classify thin melanomas; the current staging edition no longer uses it to assign stage, but pathologists still report it because a higher mitotic rate remains linked to more aggressive tumor behavior.
Margins describe the edge of the tissue that was removed. "Clear" or "negative" margins mean no melanoma cells were found at the cut edge, suggesting the tumor was fully removed. "Positive" or "involved" margins mean cancer cells reached the edge of the specimen, which usually means a re-excision is needed to remove a wider margin of surrounding skin.
These note whether melanoma cells were seen inside small blood vessels, lymphatic channels, or wrapped around nerves. When present, they suggest a higher chance the cancer has started to spread beyond the original site, and may prompt a discussion about sentinel lymph node biopsy.
Regression describes areas where your immune system appears to have attacked and partially destroyed the tumor, leaving scar-like tissue behind. Its effect on prognosis is debated among researchers, but your doctor may mention it because it can occasionally make the original tumor thickness harder to measure precisely.
TILs are immune cells found within the tumor itself. A "brisk" infiltrate—meaning lots of immune cells actively surrounding the tumor—has been associated with a somewhat more favorable outlook in some studies, though it isn't formally part of staging.
For thicker or higher-stage melanomas, your doctor may order testing for mutations such as BRAF, NRAS, or KIT. These don't change your stage, but they can open the door to targeted therapies—for example, BRAF-mutated melanomas may respond to specific oral medications that block that mutation's effects.
Your report will also name a subtype, which describes how the melanoma grew and where it tends to appear:
A pathology report can feel like a wall of jargon, but each line exists to answer one question: how is your melanoma likely to behave, and what does it need in response? Breslow depth, ulceration, margins, and the other findings all feed into your stage and your care plan.
Don't hesitate to ask your dermatologist or oncologist to walk through your report line by line—understanding it is part of being an active partner in your own care.
Disclaimer: Educational only. Not a substitute for professional medical advice. Always consult your dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for personalized information about your pathology report
Chat with the Navigator